Pyrrolocarbazoles as Checkpoint 1 Kinase Inhibitors

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)


Volume 16, 12 Issues, 2016


Download PDF Flyer




Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Michelle Prudhomme
Universite Blaise Pascal - C.N.R.S
Aubiere Cedex
France


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

Pyrrolocarbazoles as Checkpoint 1 Kinase Inhibitors



Anti-Cancer Agents in Medicinal Chemistry, 8(6): 577-597.

Author(s): Helene Henon, Elisabeth Conchon, Bernadette Hugon, Samir Messaoudi, Roy M. Golsteyn and Michelle Prudhomme.

Affiliation: Laboratoire SEESIB, Universite Blaise Pascal, UMR 6504 du CNRS, 24 Avenue des Landais, 63177 Aubiere, France.

Abstract

The carbazole framework is found in many natural compounds of biological interest. Indolocarbazoles such as rebeccamycin and staurosporine which are either a topoisomerase I inhibitor (rebeccamycin) or a non selective kinase inhibitor (staurosporine) are bacterial metabolites. In the search for new antitumor agents, DNA damage checkpoint kinases, in particular Checkpoint kinase 1, have recently emerged as attractive targets for cancer therapy. This review reports the synthesis and Chk1 inhibitory activities of pyrrolocarbazole compounds bearing four or five fused rings.

Keywords:

Checkpoint kinase 1, antitumor agents, pyrrolocarbazole, granulatimide.



Purchase Online Order Reprints Order Eprints Rights and Permissions




Article Details

Volume: 8
Issue Number: 6
First Page: 577
Last Page: 597
Page Count: 21
DOI: 10.2174/187152008785133100
Price: $58
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science